Page results
-
UCLH is celebrating the delivery of its 1,000th respiratory syncytial virus (RSV) vaccine to pregnant women, following the rollout of the new national programme in September.
-
On Saturday 25 June 2022, UCLH partnered with North Middlesex University Hospital and Whittington Health to run a summer sickle cell event at Tottenham Hotspur Stadium for children and young people with sickle cell disorder.
-
Among the many cancer clinical trials opening each year at UCLH, this year will see a focus on trials of personalised cancer treatments based on precision immunotherapies.
-
The NHS has become the first healthcare system in the world to provide a new blood group genotyping test which is set to transform care for patients living with sickle cell disorder and thalassaemia.
-
People with the acquired communication disorder aphasia – which involves problems with the understanding or production of speech –have benefitted greatly from a two-year programme of therapy at the National Hospital for Neurology and Neurosurgery at UCLH.
-
This page has been written by the team in the mitochondrial clinic for patients who are seen at the National Hospital for Neurology and Neurosurgery, who have a diagnosis of mitochondrial disease. It outlines the importance of having your heart checked as part of your care.
-
UCLH has recruited the first participant for a new UK based study for Parkinson’s Disease (PD). The ASPro-PD study is testing whether treatment with a drug called ambroxol is associated with an improvement in motor and non-motor function compared with placebo.
-
Information about the Therapeutic Plasma Exchange at NHNN for patients, carers, and families.
-
This page explains what patient-initiated follow-up (PIFU) involves after your treatment for endometrial (uterine or womb) cancer.
-
UCLH will play a vital role in a new respiratory virus study.
File results
-
FOI/2024/0155 - Immunotherapy treatments for lung cancer
-
FOI/2024/0162 - Various technology systems/ services used at Trust
-
FOI/2024/0163 - Renal cell carcinoma and melanoma treatments
-
FOI/2024/0166 - Recruitment systems/CRM platform
-
FOI/2024/0171 - Dermatology consultants
-
FOI/2024/0172 - Patients excluded from care at the Trust 2010-2023
-
FOI/2024/0179 - Water usage/ procurement
-
FOI/2024/0183 - Immunology Hidradenitis Suppurativa (HS) treatment
-
FOI/2024/0184 - IT spend/ Healthcare Information and Management Systems Society (HIMSS) EMRAM and INFRAM scores
-
FOI/2024/0190 - Scheduled appointments Did Not Attend (DNA) 2019-2023